Dilon to distribute SurgicEye imaging technologies in the U.S.

Justine Varieur Cadet | | Health Imaging | Screening
Dilon Diagnostics, a developer of molecular breast imaging technologies, has become the exclusive U.S. distributor of products from SurgicEye, developer of intraoperative soft tissue imaging and navigation technologies.

The Munich-based SurgicEye said its declipseSPECT / CSS300 provides intraoperative 3D image visualization and navigation for gamma probes during radio-guided surgery. The technology extends commonly used gamma probes and combines imaging and image viewing as a tool to resect radioactively labeled structures like primary breast tumors, metastases and sentinel lymph nodes in a minimally invasive approach. This intraoperative imaging technology contributes to quality assurance and provides evidence for sentinel lymph node and tumor resection during the surgery.

SurgicEye received FDA clearance of its declipseSPECT / CSS300 intraoperative gamma probe 3D visualization device.

 

 

Justine Varieur Cadet

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.